POSTER: CLL-542 High Rates of Undetectable Minimal Residual Disease Remissions With Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL) — an Updated Analysis
Clinical Lymphoma, Myeloma & Leukemia（2023）
关键词
CLL,MRD,BR,venetoclax,time-limited therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要